Background: Real-world data on the effectiveness and safety of lasmiditan, a new medication for acute migraine attacks, is necessary.
Methods: We performed a prospective, observational, multi-center, real-world study. A total of 48 patients with migraine (44 females, 44.6 ± 12.9 years old) were included in this study.
Results: Twenty-three patients (47.9%) reported they were headache-free two hours after taking lasmiditan and were categorized into the responder group. In total, 44 patients (91.7%) experienced at least one side effect within two hours of taking the medication. Dizziness, somnolence, malaise, nausea, and palpitations were reported by 56.3% (n = 27), 45.8% (n = 22), 37.5% (n = 18), 20.8% (n = 10), and 14.6% (n = 7) of patients respectively. Of 48 patients, 20 (41.7%) indicated that they preferred lasmiditan to their previous acute treatment. There were no predictive factors for efficacy.
Conclusion: This real-world study demonstrated the efficacy and safety of lasmiditan. More than 90% of patients experienced side effects from lasmiditan. Approximately 40% of patients preferred lasmiditan despite the occurrence of side effects.
Competing Interests: Authors’ noteThe principal investigator is Ryotaro Ishii, who had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article. Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RI has served as a consultant for Amgen K.K., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. He has received lecture fees from Amgen K.K., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., and Otsuka Pharmaceutical Co., Ltd.KI has nothing to disclose.NW has nothing to disclose.RF has nothing to disclose.MT has nothing to disclose.JN has received honoraria and research scholarships from Amgen K.K. and Daiichi Sankyo Co., Ltd.TT served as a consultant/advisor and/or served on an advisory board for Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., Amgen K.K., Teijin Pharma Limited, and Pfizer Japan. He received honoraria from Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Amgen K.K., Kowa Co., Ltd., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., UCB Japan Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Santen Pharmaceutical Co., Ltd.. He received funds from Eli Lilly Japan K.K., Pfizer Japan Inc., and Tsumura & Co. outside the submitted work.